Somatostatin treatment affects testicular function in stallions.
This study investigated the regulation of growth hormone (GH) release in stallions and tested the hypothesis that the somatotrophic axis influences testicular function. Basal plasma GH concentrations, effects of an experimental decrease of GH release on testicular function and an opioidergic regulation of GH release were investigated in Shetland stallions (n=6). No seasonal variations in plasma GH concentrations were found over a 12-month period. Treatment with the somatostatin analogue octreotid (100mg twice daily over 10 days) caused a decrease in semen motility from 38.7+/-8.4% progressively motile spermatozoa before treatment to 18.3+/-5.4% on day 3 after end of treatment (P<0.05). Values returned to 35.0+/-8.5% on day 5 after treatment. On the last day of octreotid treatment, a hCG stimulation test was performed (3000IU hCG i.v.). The hCG-induced testosterone release was significantly higher in saline treated than in octreotid pretreated animals (P<0.05). Neither plasma GH concentrations nor volume and density of ejaculates, total sperm count, or semen morphology were different between saline and octreotid treatments. Injection of the opioid antagonist naloxone (0.5mg/kg) significantly increased GH release in June (from 1.1+/-0.3ng/ml before to 3.7+/-2.2), while a minor and not significant increase occurred in January. In conclusion, our results indicate a non-seasonal basal GH release with a fine-modulation by season-dependent opioidergic mechanisms in the male horse. A transient decrease in semen motility and hCG-induced testosterone release following ocreotid treatment indicate a role of GH in the regulation of testicular function in stallions.
Aurich
Jörg E
JE
Clinic for Obstetrics, Gynecology and Andrology, University of Veterinary Sciences, Vienna, Austria.
Kranski
Stefanie
S
Parvizi
Nahid
N
Aurich
Christine
C
D000818:Animals; D013006:Growth Hormone / Q000097:blood* / Q000378:metabolism; D006728:Hormones / Q000494:pharmacology*; D006736:Horses / Q000097:blood / Q000502:physiology*; D008297:Male; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D015282:Octreotide / Q000494:pharmacology; D018847:Opioid Peptides / Q000037:antagonists & inhibitors / Q000502:physiology; D012621:Seasons; D012636:Secretory Rate / Q000187:drug effects; D013004:Somatostatin / Q000494:pharmacology*; D013081:Sperm Motility / Q000187:drug effects; D013737:Testis / Q000187:drug effects / Q000502:physiology*
D006728:Hormones; D009292:Narcotic Antagonists; D018847:Opioid Peptides; D009270:Naloxone; D013004:Somatostatin; D013006:Growth Hormone; D015282:Octreotide